| Literature DB >> 27125836 |
Alberto J Espay1, Paolo Bonato2, Fatta B Nahab3, Walter Maetzler4,5, John M Dean6, Jochen Klucken7, Bjoern M Eskofier8, Aristide Merola9, Fay Horak10,11, Anthony E Lang12, Ralf Reilmann13,14,15, Joe Giuffrida16, Alice Nieuwboer17, Malcolm Horne18, Max A Little19,20, Irene Litvan3, Tanya Simuni21, E Ray Dorsey22, Michelle A Burack22, Ken Kubota23, Anita Kamondi24, Catarina Godinho25, Jean-Francois Daneault2, Georgia Mitsi26, Lothar Krinke27, Jeffery M Hausdorff28, Bastiaan R Bloem29, Spyros Papapetropoulos30.
Abstract
The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). However, more information has not translated into a greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include noncompatible technology platforms, the need for wide-scale and long-term deployment of sensor technology (among vulnerable elderly patients in particular), and the gap between the "big data" acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open-source and/or open-hardware platforms that enable multichannel data capture sensitive to the broad range of motor and nonmotor problems that characterize PD and are adaptable into self-adjusting, individualized treatment delivery systems. The International Parkinson and Movement Disorders Society Task Force on Technology is entrusted to convene engineers, clinicians, researchers, and patients to promote the development of integrated measurement and closed-loop therapeutic systems with high patient adherence that also serve to (1) encourage the adoption of clinico-pathophysiologic phenotyping and early detection of critical disease milestones, (2) enhance the tailoring of symptomatic therapy, (3) improve subgroup targeting of patients for future testing of disease-modifying treatments, and (4) identify objective biomarkers to improve the longitudinal tracking of impairments in clinical care and research. This article summarizes the work carried out by the task force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and the quality of life of individuals with PD.Entities:
Keywords: Parkinson's disease; digital biomarkers; digital health; eHealth; precision medicine; remote monitoring; technology; wearable technology
Mesh:
Year: 2016 PMID: 27125836 PMCID: PMC5014594 DOI: 10.1002/mds.26642
Source DB: PubMed Journal: Mov Disord ISSN: 0885-3185 Impact factor: 10.338